Cor­rect­ed: FDA al­lows Curis to restart en­rolling pa­tients in leukemia tri­al as shares tum­ble 9%

Less than two weeks af­ter the FDA lift­ed a hold on one of Curis’ pro­grams, reg­u­la­tors are back with some good news.

Curis an­nounced Tues­day that the reg­u­la­to­ry agency has al­lowed the com­pa­ny to start en­rolling pa­tients again, af­ter im­pos­ing a par­tial clin­i­cal hold on the com­pa­ny’s Phase I/II study of drug can­di­date emavusert­ib in leukemia ear­li­er this year. $CRIS fell just over 9% af­ter the mar­ket opened Tues­day morn­ing, cur­rent­ly at the bor­der of pen­ny stock ter­ri­to­ry at $1.02 a share and down 1% over the course of the last month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER